Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Etanercept for ankylosing spondylitis. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives <p>Etanercept consists of two molecules of the human p75 tumor necrosis factor-alpha (TNF-#) receptor joined to the Fc portion of the human immunoglobulin G1 (IgG1). It binds soluble TNF-# with high specificity and affinity, preventing it from binding to the cell surface receptors (TNF-# receptors) on keratinocytes, thereby inhibiting its proinflammatory effects. Etanercept is prescribed=either alone or in combination with conventional treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and nonpharmacologic therapy=to reduce the signs and symptoms of ankylosing spondylitis in adult patients with long-standing active disease, who are refractory to conventional therapy alone.</p>
Timeliness warning This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly. Indexing Status Subject indexing assigned by CRD MeSH Immunoglobulin G /administration& Immunosuppressive Agents /administration& Receptors, Tumor Necrosis Factor /administration& Spondylitis, Ankylosing /drug therapy; dosage; dosage; dosage Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32006001568 Date bibliographic record published 08/12/2006 Date abstract record published 12/05/2010 |